title: [PERSIRIS study: observational study, postmarketing, prospective, to evaluate the persistence to treatment with monthly risedronate in women with osteoporosis].
abstract: OBJECTIVE
  To assess the persistence of treatment with monthly risedronate and know the reasons of persistence and nontherapeutic persistence and the profile of the non-persistent patients.
  Observational, postmarketin and prospective study.
  
  
  METHODS
  Primary care, traumatology, rheumatology, gynecology and geriatrics of Catalonia.
  
  
  METHODS
  Women with osteoporosis treated with monthly risedronate that previously had abandoned weekly bisphosphonate therapy.
  
  
  METHODS
  Percentage of patients on persistent monthly risedronate year of their prescription, reasons for persistent and non persistent and profile of non persistent patients in relation to biodemographic data, clinical data and risk factors for fracture.
  
  
  RESULTS
  289 evaluable patients with a mean age of 68.3. At 12 months of initiation with monthly risedronate, 58.1% of patients remained on treatment. Most frequent reasons for leaving: fear of having side effects and belief that the disease is typical of the age. Reasons remarkable persistence: comfort/ease and dosage. Significant differences were observed between persistent and non-persistent patients relative to: employment status, number of concomitant therapy and height; however the results of possible associated factors must be contextualized within the study characteristics and the difference in size does not seem clinically relevant.
  
  
  CONCLUSIONS
  The administration of therapeutic patterns more comfortable as monthly risedronate in osteoporosis, could facilitate persistence in patients improving the effectiveness of the drug. However in that persistence can also influence biodemographic and clinical variables and diverse of various kinds.
authors.affiliation: Medicina de Familia, CAP Les Corts (CAPSE), Barcelona, España. Electronic address: ssitjar@clinic.ub.es.
authors.forename: Salvador
authors.initials: S
authors.lastname: Sitjar Martínez de Sas
authors.affiliation: Departamento Médico Sanofi, Barcelona, España.
authors.forename: María Teresa
authors.initials: MT
authors.lastname: Aguilera de la Fuente
authors.affiliation: Medical advisor independiente, Barcelona, España.
authors.forename: Josep
authors.initials: J
authors.lastname: Combalía Romera
authors.affiliation: Medicina de Familia, CAP Les Corts (CAPSE), Barcelona, España.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Menacho Pascual
authors.affiliation: Enfermería, CAP Les Corts (CAPSE), Barcelona, España.
authors.forename: Susana
authors.initials: S
authors.lastname: González Martínez
authors.affiliation: Medicina de Familia, CAP Sants (ICS), Barcelona, España.
authors.forename: Andreu
authors.initials: A
authors.lastname: Altés Boronat
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D000068296:Risedronic Acid / Q000008:administration & dosage*; D013997:Time Factors; D016903:Drug Monitoring
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid
keywords: Medication persistence; Osteoporosis; Persistencia terapéutica; Risedronate; Risedronato